Systemic enzyme therapy in
the complex treatment of angina pectoris
Mazurov V.I., Stolov S.V., Linetskaya
N.E., Onyschenko E.F. Systemic enzyme therapy in the complex
treatment of angina pectoris. Int. J. Immunotherapy 2001, Vol. XVII,
No. 2/3/4, pp. 113-120 - ISSN 0255-9625 218 K/375 (19-05-3).
Summary: Complex treatment of stable angina pectoris (b-adrenoblockers,
calcium antagonists, aspirin, nitrates) with systemic enzyme therapy
positively affected the clinical course of the disease. The
frequency and intensity of angina pectoris attacks were reduced and
tolerance to physical load was increased. Dynamic echocardiography
revealed improved diastolic heart function. Echodensitometric study
of the myocardium in diastole showed disappearance of earlier
diagnosed areas of increased ultrasonic density. The
antiinflammatory, fibrinolytic and immunoregulatory effects of
systemic enzyme therapy are the main mechanisms responsible for its
beneficial effects.
Wobenzym® administration led to the reduction of interleukin(IL)-1b
and IL-8 cytokine levels.
Tumor necrosis factor-a levels tended to decrease. The phagocyte
concentration in monocytes and neutrophils and the nitroblue
tetrazolium (NBT)-test parameters substantially increased. The
effect of systemic enzyme therapy on coagulation, fibrinolysis and
the rheological properties of blood was evaluated, revealing an
increase in activated partial thromboplastin time index from 0.85 ±
0.04 to 0.97 ± 0.02 (p<0.05), plasma fibrinolytic activity and a
decrease in active platelets. In conclusion, administration of
systemic enzyme therapy in patients with angina pectoris is
pathogenetically justified and should be used in the complex
treatment of coronary heart disease.